Study of TUB-040 for advanced non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called TUB-040 for people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The drug is designed to target and attack cancer cells while sparing healthy tissue, potentially slowing the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has gotten worse after at least one previous treatment.
- You have at least one tumor that can be measured on a scan.
- You are able to do your daily activities (performance status 0 or 1) and expected to live more than 12 weeks.
- Your blood counts, liver, and kidney function are within acceptable levels.
- If you have had brain metastases, they must be stable and you must not be on steroids or seizure medications.
- You have not had prior treatment with a drug containing exatecan or targeting NaPi2b.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new drug called BT02 for people with advanced lung cancer that has not responded to previous treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
This trial tests a new cell therapy called BST08, made from your own immune cells, for advanced non-small cell lung cancer that has not responded to at least two standard treatments. The goal is to see if this therapy is safe and can help shrink tumors.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.